Abstract
Since its discovery palmitoylethanolamide was considered as an endogenous compound able to negatively modulate the inflammatory process. Its effects have been extensively investigated in in vitro, in vivo and in clinical studies. Notwithstanding some discrepancy, nowadays the efficacy of palmitoylethanolamide in controlling mast cell behaviour, which likely accounts for its many anti-inflammatory, anti-angiogenic and analgesic effects, is well recognized. In view of their strategic localization at sites directly interfacing with the external environment, mast cells act as surveillance antennae against different types of injury and can undergo activation, thereby regulating both innate and adaptive immune reactions through the release of several preformed and newly synthesized mediators. Mast cells are now viewed as key players in orchestrating several disorders including both acute and chronic inflammatory processes, and have a role in angiogenesis and hyperalgesia. Since mast cells exert also important physiological, homeostatic functions, the most recent goal for pharmacologists is to control, rather than block, mast cell degranulation in order to modulate the pathological scenario.
The aim of the present review is to summarise the evidence regarding the role played by palmitoylethanolamide in the control of mast cell activation, starting from in vitro studies, going through in vivo evidence in animal models of disease sustained by mast cell activation, and finally reviewing recent clinical studies using this molecule.
Keywords: Mast cells, palmitoylethanolamide, homeostasis, Autocoid Local Injury Antagonism, inflammation, pain, endocannabinoids
CNS & Neurological Disorders - Drug Targets
Title:New Insights in Mast Cell Modulation by Palmitoylethanolamide
Volume: 12 Issue: 1
Author(s): D. De Filippis, L. Negro, M. Vaia, M.P. Cinelli and T. Iuvone
Affiliation:
Keywords: Mast cells, palmitoylethanolamide, homeostasis, Autocoid Local Injury Antagonism, inflammation, pain, endocannabinoids
Abstract: Since its discovery palmitoylethanolamide was considered as an endogenous compound able to negatively modulate the inflammatory process. Its effects have been extensively investigated in in vitro, in vivo and in clinical studies. Notwithstanding some discrepancy, nowadays the efficacy of palmitoylethanolamide in controlling mast cell behaviour, which likely accounts for its many anti-inflammatory, anti-angiogenic and analgesic effects, is well recognized. In view of their strategic localization at sites directly interfacing with the external environment, mast cells act as surveillance antennae against different types of injury and can undergo activation, thereby regulating both innate and adaptive immune reactions through the release of several preformed and newly synthesized mediators. Mast cells are now viewed as key players in orchestrating several disorders including both acute and chronic inflammatory processes, and have a role in angiogenesis and hyperalgesia. Since mast cells exert also important physiological, homeostatic functions, the most recent goal for pharmacologists is to control, rather than block, mast cell degranulation in order to modulate the pathological scenario.
The aim of the present review is to summarise the evidence regarding the role played by palmitoylethanolamide in the control of mast cell activation, starting from in vitro studies, going through in vivo evidence in animal models of disease sustained by mast cell activation, and finally reviewing recent clinical studies using this molecule.
Export Options
About this article
Cite this article as:
De Filippis D., Negro L., Vaia M., Cinelli M.P. and Iuvone T., New Insights in Mast Cell Modulation by Palmitoylethanolamide, CNS & Neurological Disorders - Drug Targets 2013; 12 (1) . https://dx.doi.org/10.2174/1871527311312010013
DOI https://dx.doi.org/10.2174/1871527311312010013 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Modulating Mitochondria-Mediated Apoptotic Cell Death through Targeting of Bcl-2 Family Proteins
Recent Patents on DNA & Gene Sequences Recent Advances in Characterizing Natural Products that Regulate Autophagy
Anti-Cancer Agents in Medicinal Chemistry A Review on CRISPR-mediated Epigenome Editing: A Future Directive for Therapeutic Management of Cancer
Current Drug Targets Control of Protein Synthesis in Malignant Transformation - the Role of eIF4E and the eIF4E Binding Proteins in the Regulation of Apoptosis
Current Cancer Therapy Reviews Muscarinic Acetylcholine Receptor-Interacting Proteins (mAChRIPs): Targeting the Receptorsome
Current Drug Targets Cytotoxic Nucleoside Analogues: Different Strategies to Improve their Clinical Efficacy
Current Medicinal Chemistry Recent Patents on Proteasome Inhibitors of Natural Origin
Recent Patents on Anti-Cancer Drug Discovery The Immunomodulatory Potential of Selected Bioactive Plant-Based Compounds in Breast Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets Pyridine Based Antitumour Compounds Acting at the Colchicine Site
Current Medicinal Chemistry Biological Activity and Delivery of Peptide Nucleic Acids (PNA)-DNA Chimeras for Transcription Factor Decoy (TFD) Pharmacotherapy
Current Medicinal Chemistry Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?
Endocrine, Metabolic & Immune Disorders - Drug Targets An Overview of the α4β1 Integrin and the Potential Therapeutic Role of its Antagonists
Current Medicinal Chemistry Role of Cytokines in Regulating Feeding Behaviour
Current Drug Targets New Perspective on the Dual Functions of Indirubins in Cancer Therapy and Neuroprotection
Anti-Cancer Agents in Medicinal Chemistry HOX Genes as Potential Markers of Circulating Tumour Cells
Current Molecular Medicine Sphingosine Kinases Signalling in Carcinogenesis
Mini-Reviews in Medicinal Chemistry Mammary Development and Breast Cancer: The Role of Stem Cells
Current Molecular Medicine